Coherus Oncology, Inc.CHRSNASDAQ
Loading
Debt to Equity Over TimeElevated
Percentile Rank62
5Y CAGR-9.7%
Studio
Year-over-Year Change

Debt-to-equity ratio

5Y CAGR
-9.7%/yr
Long-term compound
Percentile
P62
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
3 yr
Consecutive growthElevated
PeriodValueYoY Change
20250.89+143.6%
2024-2.04+17.7%
2023-2.49+28.9%
2022-3.50-181.5%
20214.29+188.8%
20201.48-17.2%
20191.79+167.1%
2018-2.67-180.4%
20173.32-35.9%
20165.18-